Lansoprazol Gastroliber Pentafarma

Lansoprazole, the active ingredient in Lansoprazol Gastroliber Pentafarma, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to treat conditions such as gastroesophageal reflux disease, peptic ulcer disease and related disorders.

GNH USA supplies Lansoprazol Gastroliber Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal conditions.

- Gastroesophageal reflux disease: provides symptomatic relief and promotes healing of esophageal irritation. - Peptic ulcer disease: accelerates ulcer healing and reduces the risk of recurrence. - Erosive esophagitis: heals mucosal damage caused by acid exposure. - Helicobacter pylori eradication (as part of combination therapy): enhances eradication rates by suppressing gastric acid.

Adverse reactions may occur with lansoprazole use.

Common Side Effects: - Headache: mild to moderate pain in the head. - Diarrhea: loose, watery stools. - Abdominal pain: discomfort in the stomach area. - Nausea: feeling of sickness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Low magnesium levels: muscle cramps, irregular heartbeat, or seizures. - Clostridioides difficile infection: severe diarrhea accompanied by fever and abdominal pain.

When prescribing or dispensing lansoprazole, consider the following precautions.

- Assess renal function: adjust use in patients with severe kidney impairment. - Monitor magnesium levels: prolonged therapy may lead to hypomagnesemia. - Use with caution in hepatic impairment: liver disease can affect drug metabolism. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Review concomitant medications: evaluate for potential drug interactions. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lansoprazole can affect the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Clarithromycin: may increase lansoprazole plasma concentrations. - Ketoconazole: reduced absorption of ketoconazole when gastric pH is elevated. - Atazanavir: decreased atazanavir exposure, compromising antiviral efficacy.

Moderate Interactions (Monitor Closely): - Digoxin: possible increase in digoxin levels; monitor serum concentrations. - Methotrexate: reduced clearance may raise toxicity risk. - Calcium carbonate: may diminish calcium absorption; assess bone health.